

**Medicine summary -tranylcypromine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Case Count			122	1	62
Reaction Count	Blood and lymphatic system disorders	Aplastic anaemia	1	0	0
		Pancytopenia	1	0	0
<b>Blood and lymphatic system disorders</b>		2	0	0	
Cardiac disorders	Cardiac disorders	Tachycardia	3	0	1
		Supraventricular tachycardia	1	0	0
		Palpitations	5	0	2
		<b>Cardiac disorders</b>	9	0	3
Congenital, familial and genetic disorders	Congenital, familial and genetic disorders	Congenital brain damage	1	0	1
		<b>Congenital, familial and genetic disorders</b>	1	0	1
Ear and labyrinth disorders	Ear and labyrinth disorders	Deafness	2	0	2
		Tinnitus	2	0	2
		Vertigo	1	0	0
		<b>Ear and labyrinth disorders</b>	5	0	4
Endocrine disorders	Endocrine disorders	Hyperprolactinaemia	1	0	0
		Inappropriate antidiuretic hormone secretion	2	0	2
		<b>Endocrine disorders</b>	3	0	2
Eye disorders	Eye disorders	Xerophthalmia	1	0	1
		Eye pain	1	0	0
		Mydriasis	2	0	1
		Photophobia	1	0	0
		Blindness transient	1	0	1
		Diplopia	1	0	0
		Visual impairment	6	0	4
		<b>Eye disorders</b>	13	0	7
Gastrointestinal disorders	Gastrointestinal disorders	Tooth malformation	1	0	1
		Rectal haemorrhage	1	0	1
		Haematemesis	1	0	1
		Diarrhoea	6	0	3
		Constipation	1	0	1
		Dyspepsia	1	0	0
		Abdominal pain	2	0	1
		Dysphagia	1	0	1
		Nausea	5	0	3
		Vomiting	7	0	2
		Dry mouth	1	0	0
		Salivary hypersecretion	1	0	0
		<b>Gastrointestinal disorders</b>	28	0	14
		General disorders and administration site conditions	General disorders and administration site conditions	Hypothermia	1
Hyperpyrexia	1			0	0
Pyrexia	6			0	2
Sudden death	1			1	0

**Medicine summary -tranylcypromine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	General disorders and administration site conditions	Asthenia	3	0	2
		Fatigue	3	0	3
		Malaise	3	0	0
		Influenza like illness	1	0	0
		Face oedema	1	0	0
		Chest pain	2	0	0
		Pain	1	0	1
		Chills	3	0	1
		Drug ineffective	2	0	2
		<b>General disorders and administration site conditions</b>	<b>28</b>	<b>1</b>	<b>12</b>
	Hepatobiliary disorders	Hepatitis cholestatic	1	0	1
		Jaundice	1	0	1
		Hepatic function abnormal	1	0	0
		Hepatic failure	1	0	0
		Hepatitis	1	0	0
		Hepatotoxicity	1	0	1
		<b>Hepatobiliary disorders</b>	<b>6</b>	<b>0</b>	<b>3</b>
	Infections and infestations	Abscess	1	0	1
		<b>Infections and infestations</b>	<b>1</b>	<b>0</b>	<b>1</b>
	Investigations	Blood creatine phosphokinase increased	1	0	1
		Red blood cell sedimentation rate increased	1	0	1
		Weight increased	3	0	1
		Globulins increased	1	0	1
		<b>Investigations</b>	<b>6</b>	<b>0</b>	<b>4</b>
	Metabolism and nutrition disorders	Decreased appetite	1	0	0
		Hyponatraemia	2	0	2
		Dehydration	1	0	0
		Hyperglycaemia	1	0	0
		Hypoglycaemia	2	0	0
		<b>Metabolism and nutrition disorders</b>	<b>7</b>	<b>0</b>	<b>2</b>
	Musculoskeletal and connective tissue disorders	Systemic lupus erythematosus	1	0	0
		Arthralgia	1	0	1
		Myalgia	3	0	2
		Muscle spasms	1	0	0
		Muscle twitching	1	0	0
		<b>Musculoskeletal and connective tissue disorders</b>	<b>7</b>	<b>0</b>	<b>3</b>
	Nervous system disorders	Cerebral haemorrhage	3	0	3
		Subarachnoid haemorrhage	1	1	0
		Cerebrovascular disorder	1	0	1
		Headache	21	0	12

**Medicine summary -tranylcypromine (to end January 2009)**

			Case Group	Death Outcomes	Sole		
Reaction Count	Nervous system disorders	Amnesia	2	0	1		
		Dyskinesia	1	0	1		
		Hypokinesia	1	0	1		
		Paralysis	1	0	0		
		Tremor	6	0	1		
		Hyperreflexia	2	0	0		
		Ataxia	2	0	2		
		Nystagmus	1	0	0		
		Coma	5	0	1		
		Aphasia	1	0	0		
		Somnolence	3	0	2		
		Syncope	1	0	1		
		Dizziness	8	0	2		
		Meningism	1	0	0		
		Paraesthesia	3	0	3		
		Sensory disturbance	1	0	0		
		Dysarthria	2	0	2		
		Speech disorder	1	0	1		
		Hypertonia	5	0	1		
		Hypotonia	1	0	0		
		Neuroleptic malignant syndrome	2	0	0		
		Serotonin syndrome	7	0	1		
		Grand mal convulsion	3	0	2		
		Convulsion	6	0	0		
			<b>Nervous system disorders</b>		<b>92</b>	<b>1</b>	<b>38</b>
		Pregnancy, puerperium and perinatal conditions	Intra-uterine death		1	0	0
			<b>Pregnancy, puerperium and perinatal conditions</b>		<b>1</b>	<b>0</b>	<b>0</b>
Psychiatric disorders	Agitation		5	0	1		
	Anxiety		4	0	2		
	Nervousness		1	0	1		
	Neurosis		1	0	1		
	Bruxism		1	0	0		
	Confusional state		12	0	3		
	Disorientation		1	0	0		
	Delirium		2	0	1		
	Depression		1	0	0		
	Hallucination		2	0	0		
	Hallucination, visual		1	0	0		
	Thinking abnormal		1	0	1		
	Euphoric mood		1	0	1		
	Apathy		1	0	1		

**Medicine summary -tranylcypromine (to end January 2009)**

		Case Group	Death Outcomes	Sole	
Reaction Count	Psychiatric disorders	Aggression	2	0	2
		Withdrawal syndrome	4	0	3
		Insomnia	6	0	4
		<b>Psychiatric disorders</b>	<b>46</b>	<b>0</b>	<b>21</b>
	Reproductive system and breast disorders	Breast enlargement	1	0	0
		Erectile dysfunction	1	0	1
		<b>Reproductive system and breast disorders</b>	<b>2</b>	<b>0</b>	<b>1</b>
	Respiratory, thoracic and mediastinal disorders	Dyspnoea	2	0	1
		Respiratory disorder	1	0	0
		<b>Respiratory, thoracic and mediastinal disorders</b>	<b>3</b>	<b>0</b>	<b>1</b>
	Skin and subcutaneous tissue disorders	Urticaria	1	0	1
		Rash erythematous	2	0	0
		Photosensitivity reaction	1	0	1
		Pruritus	1	0	0
		Psoriasis	1	0	1
		Rash follicular	1	0	1
		Rash	1	0	0
		Rash maculo-papular	1	0	1
		Acne	1	0	1
		Hyperhidrosis	11	0	3
		Hirsutism	1	0	1
		Hypertrichosis	1	0	1
		Purpura	2	0	1
		<b>Skin and subcutaneous tissue disorders</b>	<b>25</b>	<b>0</b>	<b>12</b>
		Vascular disorders	Circulatory collapse	1	0
	Hypotension		6	0	2
	Orthostatic hypotension		4	0	2
	Flushing		1	0	1
	Hypertensive crisis		2	0	2
Malignant hypertension	1		0	1	
Hypertension	16		0	5	
Vasculitis	1		0	1	
<b>Vascular disorders</b>	<b>32</b>		<b>0</b>	<b>14</b>	
<b>Reaction</b>		<b>317</b>	<b>2</b>	<b>143</b>	